Xembify FDA Approval History
FDA Approved: Yes (First approved July 3, 2019)
Brand name: Xembify
Generic name: immune globulin subcutaneous, human - klhw
Dosage form: Injection
Treatment for: Primary Immunodeficiency Syndrome
Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of Primary Humoral Immunodeficiency (PI).
Development Timeline for Xembify
|Jul 4, 2019||FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.